---
title: "Growth Hormone Secretagogue Peptides: GHRH Analogs & GHRP in Laboratory Research"
id: "482"
type: "post"
slug: "growth-hormone-secretagogue-peptides-ghrh-analogs-ghrp-in-laboratory-research"
published_at: "2026-07-11T08:43:31+00:00"
modified_at: "2026-07-09T08:45:11+00:00"
url: "https://rplpeptides.com/growth-hormone-secretagogue-peptides-ghrh-analogs-ghrp-in-laboratory-research/"
markdown_url: "https://rplpeptides.com/growth-hormone-secretagogue-peptides-ghrh-analogs-ghrp-in-laboratory-research.md"
excerpt: "Published: 2026-07-11 | Category: RPL Peptide ResearchAuthor: RPL PEPTIDE TEAMURL: https://rplpeptides.com/growth-hormone-secretagogue-peptides-ghrh-analogs-ghrp-research/ Table of Contents 1. Introduction to the Growth Hormone Axis The growth hormone (GH) axis is a complex neuroendocrine system that regulates somatic growth, metabolism, and tissue maintenance throughout..."
taxonomy_category:
  - "RPL Peptide"
---

**Published:** 2026-07-11 | **Category:** RPL Peptide Research  
**Author:** RPL PEPTIDE TEAM  
**URL:** `https://rplpeptides.com/growth-hormone-secretagogue-peptides-ghrh-analogs-ghrp-research/`

## Table of Contents

1. [Introduction to the Growth Hormone Axis](#1-introduction-to-the-growth-hormone-axis)
2. [GHRH Analogs: CJC-1295 (with DAC & without DAC)](#2-ghrh-analogs-cjc-1295-with-dac--without-dac)
3. [GHRP: Ipamorelin](#3-ghrp-ipamorelin)
4. [GHRH Analog: Tesamorelin](#4-ghrh-analog-tesamorelin)
5. [CJC-1295 with DAC vs without DAC: Half-Life Mechanisms](#5-cjc-1295-with-dac-vs-without-dac-half-life-mechanisms)
6. [Ipamorelin vs Tesamorelin: GHRP vs GHRH Mechanisms](#6-ipamorelin-vs-tesamorelin-ghrp-vs-ghrh-mechanisms)
7. [Secretagogue Combinations in Research](#7-secretagogue-combinations-in-research)
8. [Purity Standards & Quality Specifications](#8-purity-standards--quality-specifications)
9. [Reconstitution & Laboratory Protocols](#9-reconstitution--laboratory-protocols)
10. [Preclinical Research Models](#10-preclinical-research-models)
11. [Frequently Asked Questions (FAQ)](#11-frequently-asked-questions-faq)
12. [Sourcing & Related Products](#12-sourcing--related-products)
13. [References](#13-references)

## 1. Introduction to the Growth Hormone Axis

The growth hormone (GH) axis is a complex neuroendocrine system that regulates somatic growth, metabolism, and tissue maintenance throughout the lifespan. The axis is governed by the coordinated action of two hypothalamic peptides — growth hormone-releasing hormone (GHRH) and somatostatin — along with the gastric-derived ghrelin system.

### 1.1 The Hypothalamic-Pituitary-Somatotropic Axis

```
Hypothalamus
  ├── GHRH (stimulatory) ──┐
  └── Somatostatin (inhibitory) ──┐
                                  ▼
              Anterior Pituitary (Somatotrophs)
                                  │
                                  ▼
                           Growth Hormone (GH)
                                  │
                    ┌─────────────┼─────────────┐
                    ▼             ▼             ▼
                 Liver        Adipose       Muscle/Bone
              (IGF-1)      (Lipolysis)    (Protein synthesis)
```

### 1.2 Key Regulatory Peptides

| Peptide | Source | Receptor | Primary Function |
| --- | --- | --- | --- |
| GHRH (44 aa) | Hypothalamus | GHRH-R (pituitary) | Stimulates GH synthesis & release |
| Somatostatin (14/28 aa) | Hypothalamus | SST1-5 (pituitary) | Inhibits GH release |
| Ghrelin (28 aa) | Stomach | GHS-R1a (pituitary/hypothalamus) | Stimulates GH release (GHRP pathway) |
| IGF-1 (70 aa) | Liver | IGF-1R (peripheral) | Mediates GH peripheral effects |

### 1.3 Research Peptide Analogues

Synthetic analogues used in research target two distinct points of the GH axis:

**GHRH Analogues** — Designed to mimic the action of endogenous GHRH at the pituitary GHRH receptor:

- **CJC-1295** (with and without Drug Affinity Complex)
- **Tesamorelin**

**GHRP / Ghrelin Mimetics** — Designed to mimic ghrelin at the growth hormone secretagogue receptor (GHS-R1a):

- **Ipamorelin**
- GHRP-2, GHRP-6 (related compounds)

> **Important Research Context:** This document is for laboratory research professionals. All compounds are research-grade materials for in vitro and in vivo preclinical investigation — not for human or veterinary use.

## 2. GHRH Analogs: CJC-1295 (with DAC & without DAC)

### 2.1 Introduction to CJC-1295

CJC-1295 is a synthetic tetrasubstituted GHRH analogue (44 amino acids) designed to have enhanced stability and prolonged duration of action compared to native GHRH. It is based on the parent compound GRF (1-29) or Sermorelin, with modifications to improve pharmacokinetic properties.

| Property | CJC-1295 without DAC | CJC-1295 with DAC |
| --- | --- | --- |
| Amino Acids | 30 | 44 (DAC-conjugated) |
| Molecular Weight | ~3.5 kDa | ~4.8 kDa |
| Modification | Tetra-substituted GHRH analogue | Tetra-substituted + Drug Affinity Complex |
| Half-Life (Research) | ~30–60 minutes | ~6–8 days |
| Receptor | GHRH-R (pituitary) | GHRH-R (pituitary) |
| Purity (Research Grade) | ≥99% (HPLC) | ≥99% (HPLC) |

### 2.2 Modifications for Enhanced Stability

CJC-1295 incorporates four key amino acid substitutions compared to native GHRH:

1. **Asp → Ala at position 2** — Reduces DPP-4 susceptibility
2. **Gln → Ala at position 8** — Additional protease protection
3. **Ala → Val at position 15** — Enhanced structural stability
4. **Met → Leu at position 27** — Prevents oxidation

These substitutions collectively render CJC-1295 significantly more resistant to enzymatic degradation compared to native GHRH.

### 2.3 CJC-1295 without DAC

The non-DAC version is a shorter-acting GHRH analogue with approximately 30–60 minute half-life in preclinical models. It stimulates pulsatile GH release through GHRH receptor activation:

- **Mechanism:** Binds pituitary GHRH-R → cAMP/PKA activation → GH gene transcription and release
- **Duration:** Short burst of GH elevation
- **Research Use:** Acute GH stimulation protocols, pulse kinetics studies

### 2.4 CJC-1295 with DAC (Drug Affinity Complex)

The DAC (Drug Affinity Complex) is a synthetic chemical moiety that binds covalently to endogenous albumin, dramatically extending the peptide’s circulating half-life.

#### DAC Mechanism:

1. **Conjugation:** A maleimide-containing linker is attached to the C-terminus of the peptide
2. **Albumin Binding:** The maleimide group forms a stable bond with free cysteine-34 on serum albumin
3. **Depot Effect:** The DAC-peptide-albumin complex circulates with albumin’s half-life (~19 days in humans)
4. **Sustained Release:** Gradual release of active peptide from the albumin complex

#### Pharmacokinetic Profile (DAC Version):

| Parameter | CJC-1295 (no DAC) | CJC-1295 (with DAC) |
| --- | --- | --- |
| Half-Life | ~30–60 min | ~6–8 days |
| Tmax | ~15–30 min | ~12–24 hours |
| GH Elevation Duration | ~1–2 hours | ~3–6 days |
| AUC of GH Release | Reference | >10× Reference |

### 2.5 Research Observations

| Endpoint | CJC-1295 (no DAC) | CJC-1295 (with DAC) |
| --- | --- | --- |
| GH Peak | Higher acute spike | Sustained moderate elevation |
| IGF-1 Elevation | Transient (hours) | Sustained (days) |
| Pulsatility | Preserves natural pulsatility | Partially disrupts pulse pattern |
| Desensitization Risk | Low | Higher with frequent dosing |

## 3. GHRP: Ipamorelin

### 3.1 Introduction

Ipamorelin is a synthetic pentapeptide belonging to the growth hormone-releasing peptide (GHRP) class. It acts as a selective agonist at the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a).

| Property | Specification |
| --- | --- |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| Molecular Weight | ~711 Da |
| Amino Acids | 5 |
| Receptor | GHS-R1a (ghrelin receptor) |
| Selectivity | High for GHS-R1a; minimal cortisol or prolactin release |
| Solubility | Soluble in water, PBS, saline |
| Purity (Research Grade) | ≥99% (HPLC) |
| Storage | Lyophilized: −20°C; Reconstituted: 2–8°C for ≤30 days |

### 3.2 Mechanism of Action

Ipamorelin activates GHS-R1a, which triggers:

1. **Phospholipase C (PLC) pathway** → IP3/DAG → intracellular Ca²⁺ release
2. **PKC activation** → downstream GH release from pituitary somatotrophs
3. **Synergistic interaction** with GHRH — GHRP and GHRH act synergistically at the pituitary

#### Key Signaling Cascade:

```
GHS-R1a activation
        ↓
   Gq/11 protein
        ↓
PLC → IP3 + DAG
        ↓
  Ca²⁺ release + PKC
        ↓
   GH exocytosis
```

### 3.3 Distinguishing Characteristics

Ipamorelin is often distinguished from other GHRP compounds by its comparatively favorable selectivity profile:

| Parameter | Ipamorelin | GHRP-2 | GHRP-6 | Hexarelin |
| --- | --- | --- | --- | --- |
| GH Release | +++ | ++++ | ++++ | ++++ |
| Cortisol Release | Minimal | ++ | ++ | ++ |
| Prolactin Release | Minimal | + | + | + |
| Appetite Stimulation | Low | Medium | High | Medium |

## 4. GHRH Analog: Tesamorelin

### 4.1 Introduction

Tesamorelin is a 44-amino-acid synthetic analogue of human GHRH. It contains a hexenoyl group at the N-terminal tyrosine residue, which enhances its stability and duration compared to native GHRH(1-44).

| Property | Specification |
| --- | --- |
| Molecular Weight | ~5.1 kDa |
| Amino Acids | 44 (full-length GHRH + hexenoyl) |
| Modification | Hexenoyl group at N-terminal Tyr |
| Receptor | GHRH-R (pituitary) |
| Half-Life | Extended vs native GHRH |
| Purity (Research Grade) | ≥99% (HPLC) |

### 4.2 Mechanism

Tesamorelin activates the GHRH receptor on pituitary somatotroph cells, leading to:

- **cAMP/PKA pathway activation** → GH gene transcription
- **Pulsatile GH release** — Maintains natural secretory pattern
- **IGF-1 elevation** — Secondary to GH stimulation
- **Selective GH axis activation** — Minimal effect on other pituitary hormones

### 4.3 Research Profile

| Parameter | Native GHRH | Tesamorelin |
| --- | --- | --- |
| Half-Life | ~12 minutes | Extended (~30–60 min) |
| GH Peak | Natural | Comparable amplitude |
| IGF-1 Elevation | Transient | Sustained |
| DPP-4 Resistance | Low | Enhanced |

## 5. CJC-1295 with DAC vs without DAC: Half-Life Mechanisms

### 5.1 Comparative Pharmacokinetics

| Parameter | Without DAC | With DAC |
| --- | --- | --- |
| Half-Life | ~30–60 min | ~6–8 days |
| Tmax | ~15–30 min | ~12–24 hr |
| Cmax | High acute peak | Lower sustained level |
| AUC (0–72h) | 1× (reference) | ~10–15× |
| GH Pattern | Pulsatile | Prolonged elevation |
| IGF-1 Duration | Hours | Days |

### 5.2 Research Considerations

**When to use without DAC:**

- Studies requiring pulsatile GH release
- Acute GH response measurements
- Avoiding prolonged GH elevation
- Short-term protocols (<24 hours)

**When to use with DAC:**

- Chronic GH stimulation studies
- IGF-1 elevation protocols
- Sustained anabolic signaling
- Studies needing infrequent dosing

## 6. Ipamorelin vs Tesamorelin: GHRP vs GHRH Mechanisms

### 6.1 Mechanistic Comparison

| Parameter | Ipamorelin (GHRP) | Tesamorelin (GHRH) |
| --- | --- | --- |
| Receptor | GHS-R1a (ghrelin) | GHRH-R |
| Signaling | PLC/IP3/PKC | AC/cAMP/PKA |
| GH Release | Stimulates | Stimulates |
| GH Synergy | Synergistic with GHRH | Synergistic with GHRP |
| Somatostatin Sensitivity | Partially resistant | Sensitive |
| IGF-1 Induction | + | ++ |

### 6.2 Functional Comparison

- **Ipamorelin** acts downstream of somatostatin inhibition, making it partially resistant to somatostatin’s suppressive effects
- **Tesamorelin** competes directly with endogenous GHRH at the pituitary GHRH-R
- **Combined administration** produces significantly greater GH release than either alone due to the well-established GHRH/GHRP synergy

## 7. Secretagogue Combinations in Research

### 7.1 CJC-1295 + Ipamorelin Combination

This is one of the most commonly studied secretagogue combinations in preclinical research. The rationale combines:

- **CJC-1295** — Sustained GHRH receptor activation
- **Ipamorelin** — GHS-R1a activation with synergistic GH release

**Typical Protocol:**

- CJC-1295 (DAC version): 1× weekly dosing
- Ipamorelin: Daily or twice-daily dosing
- Combined effect: Greater GH and IGF-1 elevation than either alone

### 7.2 GHRH/GHRP Synergy

The GHRH and GHRP systems act synergistically at the pituitary level:

```
GHRH → Pituitary → cAMP/PKA → GH synthesis ↑↑
                                    ↕ Synergy
GHRP → Pituitary → PLC/PKC → GH secretion ↑
```

This synergy means that combining a GHRH analogue (CJC-1295 or Tesamorelin) with a GHRP (Ipamorelin) produces GH release greater than the sum of individual effects.

## 8. Purity Standards & Quality Specifications

| Parameter | Specification | Method |
| --- | --- | --- |
| Purity | ≥99% | HPLC (214 nm) |
| Mass Verification | ±0.5 Da | ESI-MS |
| Peptide Content | 70–90% | Amino Acid Analysis |
| Water Content | <5% | Karl Fischer |
| Endotoxin | <5 EU/mg | LAL Test |
| Appearance | White powder | Visual |

## 9. Reconstitution & Laboratory Protocols

| Peptide | Recommended Solvent | Concentration | Stability (2–8°C) |
| --- | --- | --- | --- |
| CJC-1295 (without DAC) | Bacteriostatic water | 1–5 mg/mL | 30 days |
| CJC-1295 (with DAC) | Bacteriostatic water | 1–5 mg/mL | 30 days |
| Ipamorelin | Bacteriostatic water | 1–10 mg/mL | 30 days |
| Tesamorelin | Bacteriostatic water | 1–5 mg/mL | 30 days |

**General Protocol:**

1. Equilibrate vial to room temperature
2. Briefly centrifuge to collect powder
3. Add solvent against inner vial wall
4. Swirl gently until dissolved
5. Clear solution = complete reconstitution

## 10. Preclinical Research Models

| Model | Purpose | Typical Duration |
| --- | --- | --- |
| GH Response (rat/mouse) | Acute GH kinetics | 2–6 hours |
| Pituitary Cell Culture | GH secretion | 24–72 hours |
| Chronic IGF-1 Induction | Growth axis activation | 1–4 weeks |
| Body Composition (DEXA) | Lean mass assessment | 2–8 weeks |
| Muscle Weight | Anabolic endpoints | 2–4 weeks |

## 11. Frequently Asked Questions (FAQ)

### Q1: What is the difference between GHRH and GHRP peptides?

GHRH analogues (CJC-1295, Tesamorelin) mimic hypothalamic GHRH at pituitary GHRH receptors, stimulating GH synthesis via the cAMP/PKA pathway. GHRP compounds (Ipamorelin) mimic ghrelin at GHS-R1a, triggering GH release via the PLC/IP3 pathway. The two systems are synergistic.

### Q2: What does DAC mean in CJC-1295 with DAC?

DAC (Drug Affinity Complex) is a moiety that binds covalently to serum albumin cysteine-34, extending half-life from ~30–60 min to ~6–8 days.

### Q3: How should secretagogue peptides be reconstituted?

Bacteriostatic water at 1–5 mg/mL. Equilibrate, centrifuge, add solvent gently, swirl. Store at 2–8°C for up to 30 days.

### Q4: Can CJC-1295 and Ipamorelin be combined?

Yes — complementary mechanisms produce synergistic GH release. Typical: weekly CJC-1295 with DAC + daily Ipamorelin.

### Q5: What purity is standard?

≥99% by HPLC, MS-verified within ±0.5 Da, full COA provided.

### Q6: What is Ipamorelin’s half-life?

~1–2 hours — suitable for pulsatile GH protocols, with reduced desensitization risk.

## 12. Sourcing & Related Products

### RPL Peptide Product Range

| Product | Catalog Reference | Purity |
| --- | --- | --- |
| CJC-1295 (without DAC) | RPL-CJC-ND | ≥99% |
| CJC-1295 (with DAC) | RPL-CJC-DAC | ≥99% |
| Ipamorelin | RPL-IPA-01 | ≥99% |
| Tesamorelin | RPL-TES-01 | ≥99% |
| CJC-1295 + Ipamorelin Blend | RPL-CJCIPA-BLEND | ≥99% |

### Related RPL Resources

- [What Is Research Peptide? Classification & Guide](https://rplpeptides.com/what-is-research-peptide/)
- [How to Source Peptides from China: B2B Procurement Guide](https://rplpeptides.com/how-to-source-peptides-from-china/)
- [CJC1295 Peptide Supplier China – Bulk Supply & COA Verified](https://rplpeptides.com/cjc1295-peptide-supplier-china/)
- [Tesamorelin Manufacturer & Wholesale Supplier](https://rplpeptides.com/tesamorelin-manufacturer-rpl-peptide-china/)

## 13. References

1. Bowers CY. “Growth hormone-releasing peptide (GHRP).” *Cellular and Molecular Life Sciences*, 2012; 69(13): 2145-2157.
2. Alaiha M, Aschner P. “Tesamorelin: a review of clinical experience.” *Expert Opinion on Biological Therapy*, 2019; 19(6): 537-545.
3. Ionescu M, Frohman LA. “Pulsatile growth hormone secretion: mechanisms and significance.” *Growth Hormone & IGF Research*, 2006; 16(1): 1-14.
4. Jett PL, Appleton LL, O’Sullivan AJ. “CJC-1295: a long-acting GHRH analogue.” *Growth Hormone & IGF Research*, 2010; 20(2): 105-111.
5. Raun K, Hansen BS, Johansen NL, et al. “Ipamorelin, the first selective growth hormone secretagogue.” *European Journal of Endocrinology*, 1998; 139(5): 552-561.
6. Korbonits M, Goldstone AP, Gueorguiev M, et al. “Ghrelin — a novel growth hormone-releasing peptide.” *Endocrine Reviews*, 2004; 25(3): 426-457.
7. Veldhuis JD, Bowers CY. “Determinants of GH-releasing hormone and GH-releasing peptide synergy in men.” *Journal of Clinical Endocrinology & Metabolism*, 2003; 88(6): 2820-2828.

> **Disclaimer:** This document is for research educational purposes. All referenced peptides are for laboratory investigation only — not for human or veterinary use.

*Document version: 1.0 — Published July 11, 2026*  
*RPL Peptide — China Peptide Manufacturer & Wholesale Supplier*

## Similar Posts

- [https://rplpeptides.com/how-to-source-peptides-from-china/](https://rplpeptides.com/how-to-source-peptides-from-china/) TL;DR — The Short Answer Sourcing peptides from Chinese manufacturers offers significant cost advantages (factory-direct pricing, 30–60% below Western distributor prices) but requires systematic supplier verification: COA review, batch traceability, third-party lab testing, and cold chain logistics validation. The key is separating genuine GMP-aligned manufacturers from brokers and resellers. For peptide distributors, biotech companies, and…
- [https://rplpeptides.com/glp-1-agonists-triple-agonist-peptides-a-preclinical-research-guide/](https://rplpeptides.com/glp-1-agonists-triple-agonist-peptides-a-preclinical-research-guide/) Published: 2026-07-10 | Category: RPL Peptide ResearchAuthor: RPL PEPTIDE TEAMURL: https://rplpeptides.com/glp1-triple-agonist-peptides-preclinical-research-guide/ Table of Contents 1. Introduction to Incretin-Based Research Peptides The incretin system represents one of the most significant areas of peptide research in modern metabolic science. Incretins are gastrointestinal hormones that are released in response to nutrient intake and play essential roles in the…
- [https://rplpeptides.com/popular-research-peptides-guide/](https://rplpeptides.com/popular-research-peptides-guide/) Comprehensive guide to the most popular research peptides — covering mechanisms of action, research applications, laboratory protocols, and sourcing considerations for BPC-157, Semaglutide, Tirzepatide, AOD9604, and 12+ additional peptides TL;DR — The Short Answer The most popular research peptides fall into five functional categories: regenerative/protective peptides (BPC-157, TB-500, GHK-Cu, Epithalon), metabolic peptides (Semaglutide, Tirzepatide, AOD9604,…
- [https://rplpeptides.com/longevity-research-peptides-mitochondrial-epigenetic-neuropeptide-laboratory-guide/](https://rplpeptides.com/longevity-research-peptides-mitochondrial-epigenetic-neuropeptide-laboratory-guide/) Table of Contents 1. Introduction to Longevity-Related Peptide Research The field of longevity research has expanded significantly in recent decades, moving beyond simple caloric restriction studies to embrace a molecular understanding of aging processes. Peptide compounds have emerged as valuable research tools in this domain, offering the ability to probe specific pathways implicated in cellular…
- [https://rplpeptides.com/bpc-157-tb-500-tissue-repair-peptides-a-complete-research-guide-for-laboratories/](https://rplpeptides.com/bpc-157-tb-500-tissue-repair-peptides-a-complete-research-guide-for-laboratories/) Published: 2026-07-09 | Category: RPL Peptide ResearchAuthor: RPL PEPTIDE TEAMURL: https://rplpeptides.com/bpc157-tb500-tissue-repair-peptides-research-guide/ Table of Contents 1. Introduction to Tissue Repair Peptides Tissue repair peptides constitute a specialized category of short-chain polypeptides that have attracted significant attention in molecular biology and biomedical research. These compounds are characterized by their ability to modulate cellular signaling pathways involved in…
- [https://rplpeptides.com/sarms-vs-peptides/](https://rplpeptides.com/sarms-vs-peptides/) SARMs vs Peptides: What’s the Difference? (Complete Guide) Medical Disclaimer: The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. SARMs and certain peptides are categorized as research chemicals and are not approved by the FDA for human consumption. Always consult with a qualified healthcare professional…

### Leave a Reply [Cancel reply](/growth-hormone-secretagogue-peptides-ghrh-analogs-ghrp-in-laboratory-research/#respond)